Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Novacyt    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt : FY20 Revenue Soars 20x On COVID-19 Product Sales; Shares Down 6%

01/29/2021 | 04:12am EDT


© MT Newswires 2021
All news about NOVACYT
03/24NOVACYT  : to Launch Test For COVID-19 Variants of Concern
MT
03/24NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of CE-Mark test to detect multiple..
BU
03/17NOVACYT  : Launches Mobile Processing Laboratories For On-Site Rapid COVID-19 Te..
MT
03/17NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of Mobile Processing Laboratories ..
BU
02/24NOVACYT S.A. :  Research and Development Update
BU
02/02NOVACYT  : Launches New Tests to Diagnose Latest COVID-19 Variants; Shares Rise ..
MT
02/02NOVACYT  : Rolls Out New Product For Detection Of COVID-19 Variants
MT
02/02NOVACYT S.A. :  Launch of PCR Genotyping Assay Portfolio to Detect COVID-19 Vari..
BU
01/29NOVACYT  : FY20 Revenue Soars 20x On COVID-19 Product Sales; Shares Down 6%
MT
01/29NOVACYT S.A. : Full Year 2020 Trading Update
BU
More news
Financials
Sales 2020 312 M 371 M 371 M
Net income 2020 183 M 218 M 218 M
Net cash 2020 41,3 M 49,2 M 49,2 M
P/E ratio 2020 2,03x
Yield 2020 -
Capitalization 330 M 393 M 393 M
EV / Sales 2020 0,93x
EV / Sales 2021 1,38x
Nbr of Employees 110
Free-Float 99,3%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 4,90 €
Last Close Price 4,67 €
Spread / Highest target 22,0%
Spread / Average Target 4,88%
Spread / Lowest Target -12,2%
EPS Revisions
Managers and Directors
NameTitle
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Lisa Henriet Director-Group Operations
Andrew John William Heath Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVACYT-49.99%411
GILEAD SCIENCES, INC.11.76%81 977
MODERNA, INC.34.89%56 442
VERTEX PHARMACEUTICALS-9.73%55 220
REGENERON PHARMACEUTICALS-1.64%49 486
WUXI APPTEC CO., LTD.-1.48%45 479